Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$59.24 USD
+0.03 (0.05%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $59.30 +0.06 (0.10%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Price, Consensus and EPS Surprise
HALO 59.24 +0.03(0.05%)
Will HALO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HALO
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Other News for HALO
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
Halozyme to Present at Upcoming Investor Conferences
Top 2 Health Care Stocks That May Plunge In August
Small-cap and mid-cap Health Care has room to rally - Roth MKM
Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO)